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Effectiveness
ImplementationCardiovascular disease (CVD) is an increasingly important cause of morbidity andmortality among people living
with HIV (PLWH) now that HIV is a manageable chronic disease. Identification and treatment of comorbid med-
ical conditions for PLWH, including CVD and its risk factors, typically lack a critical component of care: integrated
care for histories of trauma. Experiences of trauma are associated with increased HIV infection, CVD risk, incon-
sistent treatment adherence, and poor CVDoutcomes. To address this deficit among those at greatest risk and dis-
proportionately affected by HIV and trauma—i.e., Black and Latinx individuals—a novel culturally-congruent,
evidence-informed care model, “Healing our Hearts, Minds and Bodies” (HHMB), has been designed to address
patients' trauma histories and barriers to care, and to prepare patients to engage in CVD risk reduction. Further,
in recognition of the need to ensure that PLWH receive guideline-concordant cardiovascular care, implementa-
tion strategies have been identified that prepare providers and clinics to address CVD risk among their Black
and Latinx PLWH. The focus of this paper is to describe the hybrid Type 2 effectiveness/implementation study de-
sign, the goal of which is to increase both patient and organizational readiness to address trauma and CVD risk
among 260 Black and Latinx PLWH recruited from two HIV service organizations in Southern California. This
study is expected to produce important information regarding the value of the HHMB intervention and imple-
mentation processes and strategies designed for use in implementing HHMB and other evidence-informed pro-
grams in diverse, resource-constrained treatment settings, including those that serve patients living in deep
poverty. Clinical trials registry: NCT04025463.
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ECH Tool for Evaluating Research Implementation ChallengesTCardiovascular disease (CVD) is a serious concern among people liv-
ing with HIV (PLWH). Antiretroviral therapy (ART) use has increased
the survival of PLWH, but CVD mortality is rising in the face of lower
overall mortality.1 After adjustment for traditional CVD risk factors,
PLWH have almost 50% higher risk for myocardial infarction (MI) than
the general population.2,3 The mechanisms underlying the association
between HIV infection, ART, and CVD risk are not fully understood, yet
factors that may contribute to this heightened risk include: HIV infec-
tion is associated with dyslipidemia and inflammation; ART agents in-
crease the risk of diabetes and dyslipidemia; and the HIV infected
population is living longer, resulting in higher rates of traditional CVD
risk factors (e.g., hypertension, diabetes, hyperlipidemia).4 Among
age-matched African American and Latinx patients, including those
with or without HIV, traditional CVD risk factors are more common or
more poorly controlled than among white patients.5 Additionally,
PLWH have high rates of traditional behavioral and social risk factors
(e.g., smoking, sedentary lifestyle, low income), and high rates of non-
traditional risk factors (e.g., Hepatitis C infection, substance use).6
A history of trauma may adversely affect healthcare utilization and
adherence among PLWH as histories of trauma and adversity are associ-
ated with decreased healthcare utilization, inconsistent treatment ad-
herence, and engagement in HIV-risk behaviors.7,8 Although PLWH
have access to HIV medical care, trauma increases their risk for treat-
ment dropout and non-adherence.9 It is estimated that 50–80% of
PLWH with histories of trauma do not fully comply with ART
protocols.10 Although the reasons for non-adherence vary, trauma is
thought to negatively impact provider-patient relationships. For exam-
ple, PLWHwith severe traumahistories tend to experiencemedical care
as both intrusive and re-traumatizing.9 A lack of supportive clinic envi-
ronments can increase exposure to trauma-related triggers.11,12 Most
PLWH do not disclose past sexual trauma to HIV providers, despite ex-
tensive evidence that psychological and behavioral correlates of theseas: A.B. Hamilton, A. Brown, T. Loeb, et al., Enhancing
..., Progress in Cardiovascular Diseases, https://doi.orgexperiences compromise HIV and other medical care engagement.13
Additional barriers to effective prevention and treatment efforts include
distrust of medical providers and institutions—particularly among
African American PLWH—coupled with disparities in quality of care.14
Conversely, trust in one's medical care providers is associated with in-
creased clinic visits, treatment adherence, and greater health and men-
tal health, regardless of ethnicity, suggesting the importance of
addressing these issues in HIV treatment paradigms.14
Post-traumatic stress disorder (PTSD) is associated with adverse
CVD outcomes, including risk for pulmonary disease and coronary ar-
tery disease.15,16 Women develop PTSD two to three times more often
than men after experiencing trauma, yet most research on the associa-
tion between trauma, PTSD, and CVD has been conducted with men.17
Amongwomen, both childhood and adult abuse are associated with in-
creased risk for diabetes, CVD, and chronic pain.18 Gender differences
have also been found between low childhood socio-economic status,
family instability, and poor health in adulthood. For example, compared
with men, the risk of MI or other CVD is more strongly associated with
adverse childhood conditions for women.19,20 Both trauma and PTSD
have been associated with physiological processes that may affect
CVD, including dysregulation in the autonomic nervous system and
the hypothalamic-pituitary adrenal axis, resulting in elevations in
blood pressure, heart rate, dysregulation of cortisol, increased secretion
of catecholamines, and inflammation.21–23 These relationships may be
greater for African American and impoverished individuals, particularly
women, who experience socioeconomic and racial/ethnic disparities in
CVD risk.24 Research is needed to examine the cumulative effects of
trauma on CVD, as repeated exposuresmay increase risk for heart attack
and other CVD, even in individuals who display few or no symptoms of
PTSD.20,24
Health systems that coordinate and integrate care across HIV and
chronic conditions such as CVD formen andwomenmayprovide the in-
frastructure needed to address the complex interplay with trauma
symptomatology (e.g., PTSD and depression). A novel, culturally-
congruent, evidence-informed care model called, “Healing our Hearts,
Minds and Bodies” (HHMB) has been designed to address patients'
trauma histories and barriers to care, and to prepare patients to engage
in CVD risk reduction. Recognizing the need to ensure that PLWH re-
ceive CVD guideline concordant care, implementation strategies have
also been developed to prepare providers and clinics to address CVD
risk among their HIV-positive patients. The goal of this study is to in-
crease both patient and organizational readiness to address trauma
and CVD risk among PLWH. The HHMB study addresses the need for
greater patient, provider, and health system focus on CVD risk in
PLWH by incorporating both implementation and effectiveness aims
using hybrid type 2 effectiveness/implementation study design,25
which have a “dual focus on effectiveness and implementation out-
comes; these designs allow for the simultaneous testing or piloting of
implementation strategies during what is otherwise an effectiveness
trial.”26 The specific aims are as follows:
(1) To assess and enhance organizational readiness for addressing
trauma and CVD risk among Black and Latinx PLWH. Specifically,
a phased approach will drive the use of implementation strate-
gies designed to educate, monitor, and support providers and
staff in adhering to CVD care guidelines;
(2) To use mixed methods to: (a) Evaluate the use and effectiveness
of implementation strategies over time, and (b) Identify barriers
and facilitators to organizational adoption of guidelines, provider
adherence to guidelines, feasibility, and sustainability; andpatient and organizational readiness for cardiovascular risk reduction
/10.1016/j.pcad.2020.02.014
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tional, and physical outcomes among 260 PLWH, specifically:
patient activation, engagement in care, knowledge of CVD
risk, adherence to clinicians' recommendations, cardiovascu-
lar health, mental health symptoms, and satisfaction with
care.
Methods/design
Overview of study design
Drawing on amulti-framework approach articulated by Damschroder
and colleagues,27 an adapted version of the Replicating Effective Programs
(REP) framework28 will guide the use of implementation strategies and
the tailoring of the HHMB intervention within the two participating im-
plementation settings. The Consolidated Framework for Implementation
Research (CFIR)29 will be used to guide the evaluation analyses.
The organizational-level sample for this study is the collaborative
network of the two clinics, both of which serve large numbers of adult
African American or Black (hereafter referred to as Black) and Hispanic,
Latino, or Latinx (hereafter referred to as Latinx) men and women ages
18 to 75with a dianosis of HIV or AIDS. It is expected that 21 staff mem-
bers across the two agencies will complete the organizational survey
and qualitative interviews, although all agency staff will be recruited
to participate. The community organization partners are similar to
those that would be likely to use HHMB and the organizational imple-
mentation strategies when the study is completed. Past collaborations
with clinic staff and the directors enhance the potential adoption and
sustainability of the HHMB program.
Participants for this study are PLWH at one of two participating
agencies who are already in care. We will use a self-controlled case se-
ries method design (i.e., patients as their own controls), wherein “only
individualswhohave experienced an event are included and all time in-
variant confounding is eliminated.”30 The outcomes for the 260 partici-
pants will be measured before and after the intervention program and
the difference in outcomes will be evaluated and analyzed. This design
is efficient and appropriate particularly when it is difficult to identify
an appropriate comparison group. We found in a previous hybrid type
2 implementation/effectiveness study that randomization (to a waitlist
control) was not feasible given the hard-to-reach population and the
population's vulnerability and need for care immediately upon express-
ing willingness to participate.31 This design also permits the focus on
providing new services rather than recruiting newpatients to the clinics
for HIV treatment. The latter new population would have to establish
trust before assessing their readiness to be involved in their own health
care and HIV treatment. As noted above, lack of trust is a factor in non-
adherence to medication and to the recommendations of health pro-
viders; this study permits the enhancement of trust rather than its ini-
tial establishment.
The patient-level sample consists of 260 Black (African American
and African) and Latinx men and women recruited from the clinics
where they have received care on at least one occasion for testing or
treatment. The power analysis is based on a sample size of 260. In
Brown et al.'s study, the total Life's Simple Seven (LS7; see below) stan-
dard deviation (SD) was 3.1 for Black participants and 3.5 for Hispanic
participants.32 Brewer et al.'s study33 found that themean LS7 scores ac-
counting for all LS7 components (range 0 to 14) were 8.8 (SD 2.5) and
8.2 (SD 2.1) at baseline and 3-month post-intervention, respectively.
Using a type I error of 0.05, type II error of 0.2 (or equivalent to power
of 80%), and a paired t-test (from baseline to 3 months), a sample size
of 260 and total LS7 SD at 3.5 level will enable us to detect a mean of
paired difference as small as 0.6 for the primary intervention outcome
of total LS7.
Participants are recruited through advertisements at the clinics and
staff awareness. Participant eligibility criteria include: 1) 18 and
75 years of age; 2) HIV-positive; 3) expecting to remain in the LosPlease cite this article as: A.B. Hamilton, A. Brown, T. Loeb, et al., Enhancing
among Black and Lat..., Progress in Cardiovascular Diseases, https://doi.orgAngeles area for at least five months; 4) agreeing to medical record re-
view for prior CVD-related test results (e.g., high cholesterol, weight
gain, a history of diabetes or high blood pressure); and 5) being willing
to participate in English or Spanish. To be eligible, clientsmust also have
N0 (i.e., at least one of the six items is endorsed) on theUCLA Life Adver-
sities Screener (LADS), a validated brief assessment of trauma and ad-
versity history that has demonstrated a strong relationship to PTSD
symptoms, depression, and anxiety (Liu et al., 2015).34 Clients must
also identify at least one CVD risk factor on the CVD Screener. This
screener was derived from the AHA LS7 Screener35 and the Cardiovas-
cular Patient Worksheet, a one-page self-report form (developed for a
Veterans Health Administration-based CVD risk reduction implementa-
tion study36) that asks clients about CVD-related illnesses, pregnancy-
related CVD complications, and family history, as well as smoking and
exercise behaviors. Individuals who participate receive a $25 incentive
for each data collection episode (pre-, post-, 3-month follow up) as
well as $20 for each HHMB intervention session attended.
Participant exclusion criteria include: 1) known psychiatric, physical
or neurological impairment that would limit their effective participa-
tion; 2) recent history of a severe illness, sexual or physical abuse that
might require sudden medical, psychological and/or legal intervention;
3) unwilling or unable to give consent to participate in the study
through completion. Referrals are provided as necessary.
Study activities and procedures are described below according to the
phased approach conceptualized in an adapted version of the REP
framework (Fig 1). All participants will provide informed consent. The
protocol is approved by the University of California Los Angeles Institu-
tional Review Board.
Phase 1: pre-conditions
Three main implementation strategies occur in this phase: (1) draft
intervention package, in collaboration with our agency partners and
consultant (CG); (2) ensure intervention fits local settings and stake-
holder priorities; and (3) identify implementation barriers (baseline
evaluation) via qualitative interviews with staff37 and a brief survey
assessing staff experience of workload (Maslach Burnout Inventory38),
climate (Implementation Climate Scale39), leadership (Implementation
Leadership Scale40), and citizenship (Implementation Citizenship Be-
havior Scale41). Survey and interviewfindingswill be used to character-
ize the participating organizations at baseline, i.e., before introducing
the intervention. This data will allow us to compare and contrast imple-
mentation processes over time, and to reflect on implementation out-
comes using this “diagnostic”42 contextual data.
Phase 2: pre-implementation
Four implementation strategies are used in this phase: (1) develop
intervention package training materials; (2) identify program cham-
pions; (3) hold orientationmeetings; and (4) pilot test the intervention.
After receiving training, facilitators at each intervention site pilot the in-
tervention with the first HHMB group of ~8 participants. Facilitators are
rated for their fidelity to the curriculum and given feedback and
debriefed after the first HHMB group at each organization. Clients are
briefly interviewed regarding comfort and satisfaction with the
intervention.
Phase 3: implementation
This phase involves: (1) technical assistance and any additional
training; (2) delivery of the HHMB intervention with a target of at
least 12 cycles of the five-week intervention over a 26-month imple-
mentation phase; (3) client-level data collection (pre-, post-, 3-month
follow-up, plusmedical record review at one-year post); (4) evaluation;
and (5) stakeholder engagement, including discussing plans formainte-
nance and evolution of the HHMB intervention package.
The Healing our Hearts, Minds and Bodies (HHMB) intervention. HHMB is
a psychoeducational, trauma-focused intervention derived from threepatient and organizational readiness for cardiovascular risk reduction
/10.1016/j.pcad.2020.02.014
Fig. 1. Adapted Replicating Effective Programs (REP) framework (adapted from Kilbourne et al.28 and Hamilton et al.36) enhanced with the Tool for Evaluating Research Implementation
Challenges64 and Periodic Reflections65
4 A.B. Hamilton et al. / Progress in Cardiovascular Diseases xxx (xxxx) xxxevidence-informed programs: Healing Our Women (HOW), Emotional
Emancipation Circle (EE Circle), and Diabetes Prevention Program
(DPP). HOW is an evidence-based intervention originally designed for
HIV-positive women targeting sexual risk behavior, medication adher-
ence, and psychological distress.43 Components of HOW were adapted
to the study population and components of the EE Circle Model44
were added. EE Circles address the historical and contemporary traumas
of enslavement, oppression, racism, and discrimination. These two
models combined serve as the primary foundation for addressing the
traumatic experiences that the Black and Latinx study population is
likely to have experienced in their personal and collective racial group
histories.
The final component of theHHMB intervention draws upon relevant
concepts in the evidence-based Diabetes Prevention Program.45 In the
Action Plan for Health component of the intervention, participants incor-
porate CVD risk reduction using a CVD scorecard based on the American
Heart Association LS7/MyHealthyHeart program.46 The scorecard iden-
tifies seven biologic and behavioral risk factors for CVD andwhether the
participant is at goal, in the caution range, or not at goal for each risk fac-
tor. Participants choose one risk factor that is out of range towork on (in
collaboration with the class facilitator). The classes provide information
on all seven CVD risk factors, which are either self-reported (healthy
diet, physical activity, smoking) or measured as part of the study
(blood pressure control, healthy weight, cholesterol and blood sugar
control). Two risk factors (i.e., cholesterol and blood sugar control) are
also obtained from the patient's electronic health record available at
both agencies. Two composite scores are also constructed for each par-
ticipant: a 5-item score without blood sugar or lipid levels and a 7-item
score consisting of all the items. The 5-item score is measured immedi-
ately after the end of the intervention (approximately six weeks after
the baseline measurements), as changes in LDL cholesterol and A1c
would not be expected in that time period.
HHMB targets cognitive, affective, and behavioral dimensions that
ultimately affect the targeted psychological and biological outcomes.
For example, within the cognitive dimension, the intervention targets
the following skills/practices: the role and disclosure of trauma; identi-
fying triggers to poor health habits and decisions; counter-narratives,
schemas, and cognitive self-monitoring. Through expressive writing,47
guided discussion, and group experiential activities, participants ex-
plore the role that trauma plays in their psychological and physicalPlease cite this article as: A.B. Hamilton, A. Brown, T. Loeb, et al., Enhancing
among Black and Lat..., Progress in Cardiovascular Diseases, https://doi.orgfunctioning, learn to identify triggers from previous trauma that precip-
itate poor coping and health practices, and develop counter-narratives
and new schemas for more effective coping andmanagement of trauma
to ameliorate the effects of racism and racial stress on health and well-
ness. Within the affective domain, the following skills/practices are
targeted: relaxation techniques, mindfulness, and self-monitoring of
mood states. Participants learn and practice relaxation techniques and
a mindfulness approach of attention to the present moment, as well as
how to monitor one's own mood states. These practices have demon-
strated positive effects on anxiety reduction. Within the cognitive do-
main, using the EE Circles, participants are guided through a process
of critical consciousness about cultural trauma and its effects related
to a dramatic loss of identity and meaning and racial group cohesion.48
Although compensation for participation may limit the generaliz-
ability of the results, experience indicates that incentives enhance at-
tendance and active participation, which are essential for treatment
effectiveness. Therefore, participants are given compensation for each
data collection episode and intervention session attended as well as
for transportation costs and cellular phone air timeminutes to facilitate
regular communication. Usual care, services, and referrals are available
to all clients before, during, and after the intervention.
The self-report assessment protocol developed for previous studies
and pre-programmed using audio computer-assisted self-interviewing
(ACASI)49 takes about 90 min to complete. ACASI provides both audio
and video presentation of the questions and response options on a lap-
top computer. ACASI has been shown to significantly decrease social de-
sirability bias. If a participant becomes distressed during assessment,
the session is stopped, brief support provided, and the participant is re-
ferred for mental health services.
We will also conduct clinical data collection during the intake ses-
sion to complete the LS7 score (see below). The HHMB consent form re-
quests permission to review clinical data from the electronic health
record. The data requested include CVD risk factor processes and inter-
mediate outcomes, including body mass index, blood pressure, hemo-
globin A1c (A1c), and lipid profiles.
Baseline and outcome measures
Psychological health.Depression symptoms are assessedwith the 21-
item Beck Depression Inventory Il (BDI-11), a self-report questionnaire
designed to assess symptoms of Major Depressive Disorder.50 Post-patient and organizational readiness for cardiovascular risk reduction
/10.1016/j.pcad.2020.02.014
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traumatic Diagnostic Scale (PDS) that yields a reliable sum score.51 Gen-
eral anxiety is assessedwith the Patient Health Questionnaire-15 (PHQ-
15),52 based on the diagnostic criteria for anxiety. Emotional regulation
is assessed with the Short Form of the Difficulties in Emotional Regula-
tion Scale (DERS).53 This 18-item short version is highly correlatedwith
the original 36-item form and demonstrates good validity and reliabil-
ity. Sleep habits are measured with items from the Pittsburgh Sleep
Quality Index (PSQI).54
The main effectiveness outcome is the LS7 score. The LS7 is a set of
national goals developed by the American Heart Association to define,
monitor, and enhance cardiovascular health through the primary pre-
vention of heart disease and stroke,55 and to track health disparities.32
The LS7 score summarizes control of three health factors (blood pres-
sure, serum lipids, and blood glucose levels) and four health behaviors
(physical activity, diet,maintaining a healthyweight, and not smoking).
Lower scores are associated with higher all-cause and CVD-related
mortality56 and with a higher incidence of CVD,57 stroke,58 heart
failure,59 cognitive impairment,60 depressive symptoms,61 and end-
stage renal disease.62 Diet, physical activity, and smoking are obtained
through the survey and blood pressure is measured by the study team
at baseline (pre-), approximately oneweek after completion of the clas-
ses (post-), and at three months. A1c and lipids are measured with
blood spots at baseline and three months. The A1c is measured with
the DCA Vantage® Analyzer (Siemens); non-fasting cholesterol levels
(total, LDL, andHDL) and triglycerides aremeasured using a CardioChek
PA Analyzer (CardioChek).
Table 1 details definitions of poor, intermediate, and ideal levels for
each LS7 component.55,63 To score each LS7 component, we assign 2
points to the ideal category, 1 point for intermediate values, and zero
points to the poor category. Total LS7 score is calculated for each partic-
ipant by summing the scores for all seven components, with a resulting
range from 0 to 14.
Evaluation. Several types of assessments are used to track implementa-
tion processes, specifically with regard to fidelity, dose, and intensity of
intervention. Throughout the intervention, various factors are moni-
tored such as session attendance, session completion, and participant
satisfactionwith sessions. Facilitators complete short surveys noting ad-
herence to the curriculum, level of participation, specific obstacles that
may have arisen, and what components appear to be most/least appro-
priate for the session's participants. Facilitators also complete overall
ratings of each participant's engagement, competency, and knowledge.
To assess fidelity, sessions are digitally recorded. A random sample of all
session recordings will be reviewed and scored for fidelity to core ele-
ments, with a criterion of 80% or more of the total elements considered
acceptable.
To assess the impact of implementation challenges, we use the Tool
for Evaluating Research Implementation Challenges (TECH),64 which is
recommended under three pre-conditions: 1) when “implementation
adaptations are expected due to the emergent nature of complexTable 1
Life's simple seven cardiovascular health metrics and definitions.
Health metric Poor (scored = 0) Intermediate (scored = 1)
Blood pressure SBP ≥ 140 or
DBP ≥ 90 mmHg
SBP 120–139 and DBP 80–89
ideal goal
Total cholesterol ≥240 mg/dL 200–239 mg/dL, or treated to
A1c ≥5.7% 5.0–5.6
Body mass index ≥30 kg/m2 25–29.9 kg/m2
Physical activity a None Under 30 min moderate exer
Fruit and vegetable servings
per day
0 1–4
Smoking Current Former, stopped ≤12 months
Abbreviations: SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure.
a Healthy diet score is calculated using four components of the Health Eating Index (fruits, v
dietary guidance.
Please cite this article as: A.B. Hamilton, A. Brown, T. Loeb, et al., Enhancing
among Black and Lat..., Progress in Cardiovascular Diseases, https://doi.orgresearch settings;” 2) the research environment needs to encourage
“spontaneous emergent solutions” and creativity; and 3) all research
team members must be empowered to participate. The study settings
and approach meet these pre-conditions. TECH, which has been used
successfully in community studies, is codified into a series of interactive
steps: identifying challenges (e.g., through observing day-to-day dy-
namics, listening to complaints, asking questions, etc.), interpreting
the challenges in weekly meetings, generating and testing solution
strategies, and, if necessary, addressing regulatory issues. Solution strat-
egies are developed through open dialogue among the team members
as well as others who might have perspectives on potential solutions.
The TECH is complemented with the periodic reflections method de-
signed to capture implementation progress and document use of imple-
mentation strategies (see Fig. 1).65 Approximately 13 months into
implementation, key stakeholders are asked to participate in mid-
implementation qualitative interviews to evaluate the value of the im-
plementation strategies, barriers and facilitators to implementation,
and recommendations for the remainder of the implementation phase.
Phase 4: Maintenance and Evolution
Phase 4 involves: (1) evaluating current practices and organizational
incentives to facilitate long-term adoption; (2) preparing the interven-
tion package for dissemination; based on feedback from clients and key
stakeholders, the teamwill make adjustments to the intervention pack-
age and encourage sites to continue using HHMB, as well as the tech-
niques used to evaluate guideline-concordant care; (3) recustomizing
delivery as need arises; dependingon implementation and effectiveness
outcomes, the organizations may elect to recustomize the intervention
and/or the organizational-level implementation strategies; and (4) pre-
paring implementation tip sheets in collaborationwith agency partners;
depending on implementation and effectiveness outcomes, these sheets
will be designed to scale-up and spread the approach to other organiza-
tions serving Black and Latinx PLWH.
Data analysis and statistical modeling plan
Qualitative data document how the participating organizations are
supported in implementing and sustaining the intervention. The focus
is on describing the process of assisting the organizations with imple-
mentation and maintenance. This description and summary is gener-
ated from interviews and notes from project calls, along with other
qualitative data gathered throughout the study.
To evaluate the use and effectiveness of implementation strategies
over time, and identify barriers and facilitators to organizational adop-
tion of guidelines, provider adherence to guidelines, feasibility, and sus-
tainability, the Consolidated Framework for Implementation Research
(CFIR)29 is used as a guide. CFIR provides an analytic rubric for examin-
ing intervention and provider characteristics, as well as inner and outer
settings. Data regarding acceptability, barriers, and facilitators are de-
rived from interviews and implementation-focused evaluation mea-
sures. Descriptive statistics are used to analyze the survey data givenIdeal (scored = 2)
mmHg or treated to SBP b 120 and DBP b 80 mmHg and not on blood pressure
medications
ideal goal b200 mg/dL, and not on lipid lowering medications
b4.9
b25 kg/m2
cise 3 days per week ≥ 30 min moderate exercise at least 3 days per week
≥5
ago Never smoked or quit N12 months ago
egetables, grains and sodium), a diet quality scale that assesses conformance to federal
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the agencies in preparation for implementation. In addition, facilitator
and participant satisfaction ratings are evaluated to characterize accept-
ability of the intervention. These ratings are compared both within and
across cohorts and organizations.
Potential determinants of adoption and fidelity include but are not
limited to training factors, competency at delivering the intervention,
types of facilitators, participant gender and racial/ethnic diversity in a
given cohort, retention, and satisfaction. These factors are examined
when characterizingfidelity across agencies. In addition, based on inter-
viewswith facilitators and clients, other determinantsmay emerge dur-
ing implementation. There are several possible determinants of
maintenance. It is hypothesized that maintenance will be achieved in
agencies that have their own trained staff facilitatorswhodeliver the in-
tervention with fidelity and who had positive experiences with the in-
tervention during the implementation phase.
Qualitative data analysis
All interviews are digitally recorded and transcribed by a profes-
sional transcription company. Analysis will be conducted using ATLAS.
ti, a software package that allows for fluid “interaction” of data types
and sources. Using constant comparison analytic methods,66 a prelimi-
nary codebook will be developed both deductively using CFIR and
inductively from a sub-sample of interviews within and across organi-
zations at baseline. Qualitative findings at baseline are augmented by
preliminary analyses of staff-level data from the survey described
above, and a baseline profile developed for each agency. These profiles
are reviewed by the Implementation Team, and used to tailor imple-
mentation strategies at each site (e.g., where there is a high level of
burnout, additional attention will be paid to supporting staff and man-
aging workload throughout implementation).
This approach of using baseline data as diagnostic and informative
for tailored implementation has been employed in a prior implementa-
tion study.67 The codebookwill be elaborated upon and adjusted as each
round of interviews is reviewed. Interviews will be compared within
each organization, across organizations, across different types of re-
spondents, and over time. Additional sources of qualitative data
(i.e., meeting minutes, periodic reflections, archival information) will
also be included in the data set. The data will be analyzed specifically
for barriers to and facilitators of implementation, including but not lim-
ited to the ways in which the project's implementation strategies affect
adoption, satisfaction, and maintenance. In addition to identifying
themes and patterns qualitatively, statistical associations will be exam-
ined between important process and outcomevariables such as satisfac-
tion with the intervention, fidelity, and retention, and improvement in
clinical and behavioral outcomes. Agency profiles will be revisited and
further developed at the end of the active implementation phase, and
again after implementation, thereby creating a story of implementation
at each organization.
Quantitative data analysis
To evaluate the clinical outcomes and the effects of the intervention,
systematic data analysis and statistical modeling will be conducted:
(1) For univariate analysis, the marginal distribution of each measure
obtained will be calculated at each time point and across time. For
categorical variables (e.g., gender, and race/ethnicity), the frequency
distribution and modes will be calculated. For continuous measures
(e.g., blood sugar levels/A1c), the central tendency (mean and median)
will be calculated, variation (e.g., standard deviation, kurtosis), percen-
tiles and range. Statistical tests (e.g., Shapiro-Wilk test) will be used to
assess normality of the outcomes. The degree and patterns of
missingness will be determined, and we will perform imputation
(e.g., multiple imputation), if needed. (2) Bivariate analyses of each out-
come measure and independent variables will be carried out. PearsonPlease cite this article as: A.B. Hamilton, A. Brown, T. Loeb, et al., Enhancing
among Black and Lat..., Progress in Cardiovascular Diseases, https://doi.organd Spearman rank correlation will be used to correlate predictors
with outcome measures. t-tests, analysis of variance (ANOVA) or mar-
ginal regressions will be used for continuous measures. The change
(delta) of outcome measures between time-points will be calculated,
and distributions of the deltas will be carefully examined. The bivariate
analyses between the deltas and covariates will be carried out. Marginal
repeated measures models will be carried out between each indepen-
dent measure and outcomes over time. (3) Multivariate repeated mea-
sures modeling68,69: To evaluate the relationships between outcome
measures and independent variables over time, generalized linear
mixed effect models (GLMEM) will be fitted, controlling for age and
others factors. Graphical analyses (e.g., parallel plots) will be used to as-
sist in examining the relationship between predictors and outcome
measures over time. Potential non-linear relationships between the
outcome measures and the continuous predictors will be explored
through generalized additive mixed models.
Discussion
This study incorporates several innovative features. First, it shifts
current clinical paradigms by focusing on the nexus of HIV, CVD risk,
and individual and cultural trauma histories among Black and Latinx in-
dividuals in theUS, who are disproportionately affected by each of these
factors. The use of trauma history screening using an innovative com-
posite trauma exposure risk index captures traumaexperiences not typ-
ically asked about in healthcare settings. This project is the first to
investigate how brief trauma interventions can prepare PLWH to ad-
dress concurrent health conditions such as CVD risk, particularly within
community-based healthcare contexts that are also addressing these
health conditions. Importantly, integrated HIV and chronic disease ser-
vices show promise for better outcomes among PLWH who have co-
morbid conditions,70 but to date, there is a dearth of U.S. literature on
how to integrate services, how to support guideline-concordant ser-
vices for co-morbid conditions, and how to ensure that patients are
ready to access those services and engage in appropriate care. This
study provides an opportunity to shape and facilitate two complemen-
tary pathways to improved CVD care: the patient pathway and the
organizational pathway. With blended, REP-guided implementation
strategies71 supporting both pathways, it is expected that CVD out-
comes will be improved and CVD-related services will be strengthened
and maintained.
Second, to address multiple co-morbidities, implementation science
literature stresses the importance of multifaceted, modular, flexible
interventions72–74 rather than interventions focused on singular condi-
tions and/or interventions that pose fidelity challenges in usual care set-
tings. The proposed intervention, Healing our Hearts, Minds and Bodies
(HHMB), represents an improvement over existing interventions in that
it: addresses multiple, interrelated conditions; draws on a combination
of evidence-based, evidence-informed, and culturally congruent ap-
proaches to individual and cultural trauma, HIV, and CVD risk43; reduces
barriers to accessing CVD care for a diverse cohort of patients with com-
plex needs75,76; is specifically intended for populations most impacted
by HIV; is group-based, brief, and tailorable to local context; and can
be facilitated by a trained staff member with minimal prior experience
of delivering mental health/CVD interventions. As such, it falls within
the concept of a “disruptive innovation,”77with its emphasis on simplic-
ity, accessibility, and potential scalability, should favorable effectiveness
and implementation outcomes be achieved.
Third, extensive implementation research across varied settings and
with diverse populations78–80 has been used to propose innovative
methods to comprehensively capture the complexity of implementa-
tion, adaptations to the intervention, and real-time use of implementa-
tion strategies that are tailored to local contexts. A persistent challenge
in implementation research has been to capture the dynamic nature of
change over the course of implementation.81 Ourmethods for capturing
this complexity offer a more ethnographically oriented approach.65patient and organizational readiness for cardiovascular risk reduction
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cluding 1) potential for being underpowered to detect significant effects
on any one of the LS7 factors, since participants will be working on
different factors; 2) lack of generalizability to other PLWH patient pop-
ulations with histories of trauma; and 3) small number of implementa-
tion sites, possibly limiting applicability of implementation strategy
implications.
A recent systematic review of programs that integrated CVD, hyper-
tension, and diabetes with HIV services found that these programs
showed promise in coordinating care for the rising number of patients
living with HIV and CVD or its risk factors, often leveraging existing
HIV and AIDS services.70 However, few of these programs were based
in the United States, and there was limited evidence of their long-
term impact. Health systems, such as our participating clinics, that
work to coordinate and integrate care acrossHIV and chronic conditions
such as CVDmay provide the infrastructure needed to address the com-
plex interplay of these conditions. Their ability to do somay be strength-
ened by our intervention's explicit recognition of and care for individual
and cultural histories of trauma. Should successful outcomes in this hy-
brid effectiveness-implementation study be achieved, the intervention
and accompanying implementation strategies will be refined to support
reach to other vulnerable populations (e.g., Black and Latinx PLWHwho
are not currently in care, other populations disproportionately affected
by HIV) and to more organizations that serve these populations.
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